Keudell Morrison Wealth Management Has $735,000 Stake in Novo Nordisk A/S (NYSE:NVO)

Keudell Morrison Wealth Management lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 4.6% during the 4th quarter, Holdings Channel reports. The fund owned 8,548 shares of the company’s stock after acquiring an additional 378 shares during the quarter. Keudell Morrison Wealth Management’s holdings in Novo Nordisk A/S were worth $735,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Institute for Wealth Management LLC. increased its position in Novo Nordisk A/S by 22.3% in the 4th quarter. Institute for Wealth Management LLC. now owns 15,823 shares of the company’s stock valued at $1,361,000 after acquiring an additional 2,881 shares in the last quarter. Fortune Financial Advisors LLC grew its stake in shares of Novo Nordisk A/S by 2.1% during the fourth quarter. Fortune Financial Advisors LLC now owns 27,386 shares of the company’s stock valued at $2,356,000 after purchasing an additional 568 shares during the last quarter. Cibc World Market Inc. raised its position in Novo Nordisk A/S by 6.2% in the 4th quarter. Cibc World Market Inc. now owns 658,463 shares of the company’s stock worth $56,641,000 after purchasing an additional 38,689 shares during the last quarter. Capital Investment Advisory Services LLC lifted its holdings in Novo Nordisk A/S by 4.4% during the 4th quarter. Capital Investment Advisory Services LLC now owns 9,919 shares of the company’s stock worth $853,000 after buying an additional 422 shares in the last quarter. Finally, Busey Bank boosted its position in Novo Nordisk A/S by 108.5% in the 4th quarter. Busey Bank now owns 106,434 shares of the company’s stock valued at $9,155,000 after buying an additional 55,380 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $85.33 on Friday. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $382.91 billion, a PE ratio of 27.61, a PEG ratio of 0.92 and a beta of 0.45. The stock’s fifty day simple moving average is $93.97 and its 200 day simple moving average is $113.62.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.